Moleculin’s Annamycin Extends Survival by More Than 60% in Metastatic Pancreatic Cancer Preclinical Models - Data Presented at AACR 2026
Moleculin presented preclinical data at AACR 2026 showing its lead drug Annamycin extended median survival by more than 60% in metastatic pancreatic cancer models (29 days vs 18 days, p=0.0003). The data demonstrated significant tumor growth inhibition across multiple PDAC models (p<0.001) and higher tumor accumulation than doxorubicin (p<0.0001), while maintaining absence of cardiotoxicity.
Key figures
- Drug Name
- Annamycin
- Phase Of Trial
- preclinical
- Median survival days
- 29 vs 18
- Statistical significance
- p=0.0003
- Survival extension percent
- >60%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.